Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099590 · ClinicalTrials.gov registry record · Phase 2
Alkontrol-herbal Effects on Alcohol Drinking
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03099590 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 28 participants.
The verdict
NCT03099590, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal (Isoflavone; Kudzu) has on alcohol intake in a population seeking treatment for an alcohol use disorder.
Interventions
- DIETARY_SUPPLEMENT Placebo control
- DIETARY_SUPPLEMENT kudzu extract, puerarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099590
The ClinicalTrials.gov registry entry for NCT03099590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT03099590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099590 about?
NCT03099590 is a clinical study titled "Alkontrol-herbal Effects on Alcohol Drinking". Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal (Isoflavone; Kudzu) has on alcohol intake in a population seeking treatment for an alcohol use disorder.
What is the current status of trial NCT03099590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-01-01. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03099590?
The interventions under investigation include: Placebo control (DIETARY_SUPPLEMENT), kudzu extract, puerarin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03099590?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.